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In 2006, the Society for Vascular Surgery began development of clinical practice guidelines to assist clinicians in the process of
decision making. The Society selects clinical questions of high impact and evaluates the totality of evidence by identifying and
conducting rigorous systematic reviews. Multidisciplinary committees follow the Grading of Recommendations, Assessment,
Development and Evaluation framework (GRADE), standard consensus, and voting procedures. Factors other than evidence,
including patients’ values and preferences and the availability of surgical expertise, are also considered. We describe, in the
context of cumulative 4-years’ experience, the methods and rigor of current procedures adopted by the Society for Vascular
Surgery in developing practice guidelines. We also discuss potential future efforts needed to maximize the quality, adoption,
and application of the clinical recommendations. (J Vasc Surg 2011;53:1375-80.)
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tIn vascular surgery, clinical practice structured after the
principles of evidence-based medicine has become critical
as newer technologies evolve, requiring better knowledge
of the associated benefits and harms to help surgeons and
patients in their decision making. In addition, the field of
surgery has entered an era of limited health care resources,
mandating that interventions are not only safe and effica-
cious, but also cost-effective.
Evidence-based medicine has been defined as “the con-
scientious, explicit, and judicious use of current best evidence
in making decisions about the care of individual patients” and
involves integrating evidence with clinical expertise, the pa-
tient’s values and preferences, and the availability of societal
resources.1 Unfortunately, as the literature has expanded
comprehensive knowledge of the literature and the accurate
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ients has become increasingly difficult for busy clinicians.
In 2006, the Society for Vascular Surgery (SVS) began
evelopment of clinical practice guidelines to assist practic-
ng clinicians in the process of decisionmaking. To this end,
xpert vascular specialists and methodologists have worked
ogether to streamline and standardize the guideline pro-
ess. We describe the methods and rigor of the current
rocedures adopted by the SVS in developing practice
uidelines and discuss potential future efforts needed to
aximize the quality, adoption, and application of the
linical recommendations.
HE GUIDELINE PROCESS
ackground
The SVS process of guideline development began in
006 with the appointment of a practice guideline commit-
ee and the identification of areas warranting guideline
evelopment. Subsequently, a 1-day retreat under the
uidance of experts in the field was conducted to help
stablish a common framework for development of evidence-
ased guidelines. Individual committees were then given
he task of developing topic-specific guidelines.
teps in developing guidelines
Selection of committees. The SVS Practice Guideline
ommittee appoints a chair to lead each guideline group.
he Chair selects several committee members (surgeons
nd non-surgeons) with expertise in the particular area of
he guidelines. The selection of the Chair and the members
epends on expertise, scientific contributions (publications
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May 20111376 Murad et aland presentations), and national reputation. The commit-
tees are multidisciplinary and include in addition to vascular
surgeons a methodologist and representatives of other spe-
cialties when relevant. For example, for guidelines on man-
agement of dialysis access,2 the committee included non-
vascular access surgeons and nephrologists. The venous
guidelines were done jointly withmembers of the American
Venous Forum, a multidisciplinary society dedicated for
education and research in venous disease as well as a phle-
bologist with experience in drug therapy and compression
treatment. Carotid and thoracic guidelines included vascu-
lar and endovascular surgeons.3-5
Identification of critical clinical questions. Each
guideline committee engages in discussion and negotiations
with methodologists with expertise in evidence synthesis.
Methodologists assist in defining the questions at hand and
determine whether high-quality and up-to-date systematic
reviews or technology assessment reports are available in the
published literature. If these reports are unavailable, they
would be created de novo. To represent the current state of
the literature, existing systematic reviews may need to be
updated, which involves reappraisal of previously synthesized
evidence, as well as a search for new evidence. For example, a
well-conducted systematic review comparing endarterectomy
and stenting6 was updated in the process of developing guide-
lines for the management of carotid disease.7
Evidence synthesis
Systematic reviews and meta-analysis. Systematic re-
view of the literature is essential in the development of evi-
dence-based clinical practice guidelines because it allows eval-
uation of the totality of the existing evidence base and
appraisal of its quality whileminimizing bias in the selection of
evidence sources. The guideline committee and the method-
ologist develop a protocol for the systematic review that
incorporates study inclusion criteria and specifies data to be
extracted from the literature on the basis of critical clinical
questions chosen in the previous step. Themethodologist and
an expert reference librarian develop a search strategy that
undergoes multiple testings and iterations and spans numer-
ous databases. The methodology group reviews and selects
studies, following prespecified inclusion criteria; appraises the
quality of evidence; and extracts outcome data.
Meta-analysis and meta-regression are performed if
data are amenable to quantitative analysis; otherwise, data
are described qualitatively. Although some meta-analysts
prefer to conduct meta-analyses on randomized trials only,
the SVS and the methodology group have opted to system-
atically synthesize evidence from observational studies and
case series as well. Evidence synthesis in the form of system-
atic reviews and meta-analyses is considered the best ap-
proach because it (1) offers opportunity to evaluate the
totality of evidence in a systematic, reproducible way, (2)
incorporates measures to reduce bias in selecting the source
of evidence and extracting data, (3) increases the precision
of the estimated treatment effects (by meta-analysis), (4)
explores the sources of inconsistency in effects across stud-
ies, and finally, (5) provides inferences that apply to a wider Cange of patients than possible with each study individu-
lly.8 Indeed, some empiric research suggests that meta-
nalyses of well-designed, nonrandomized comparative
tudies of surgical procedures may yield inferences similar
o meta-analyses of randomized controlled trials.9 The
ingering challenge in these cases is that guideline develop-
rs cannot be sure whether this is the case in the literature at
and—in the absence of the randomized trials. In most
ircumstances, observational studies provide less confi-
ence in the estimate of treatment effect.8
A liaison or guideline committee representative usually
s involved in some aspects of the evidence synthesis process
o provide clinical context. In addition, a methodology
roup representative is involved in the guideline formula-
ion process to ensure optimal interpretation of the evi-
ence. Despite this overlap, the two processes are separate;
o reduce potential biases, the guideline committee does
ot have a role in evidence selection.
After systematic reviews are identified or conducted,
he methodologists create evidence profiles that describe
he quality of evidence and the relative and absolute treat-
ent effects, including measures of precision. It is appreci-
ted that randomized clinical trials and well-conducted
bservational studies are not always available to provide
uidance for every clinical question in vascular surgery.
herefore, the formal meta-analysis of comparative studies
ccasionally is supplemented with lower-quality evidence
nd with explicit acknowledgment.
Consensus statements. When direct comparative evi-
ence is not available to guide clinical recommendations,
ommittees occasionally have provided guidance using their
linical experience, unsystematic observations, and best inter-
retation of the low-quality evidence available in a particular
urgical area. Such evidence may be derived either from case
eports, single surgical center experience, or indirect evidence
rom studies in populations other than the population ad-
ressed by the recommendation or from experiments that
sed surrogate end points or laboratory or physiologic end
oints. An example of this occurrence is in the guidelines for
he management of the left subclavian artery during endovas-
ular thoracic aortic repair.4 The guideline committee identi-
ed to the best of its members’ ability certain conditions in
hich patients’ anatomy may lead to compromised perfusion
o the brain, spinal cord, heart, or left arm and in whom
outine preoperative left subclavian arterial revascularization is
ore critical. Evidence to guide identification of such condi-
ions was scarce and indirect.
Guideline developers in fields other than vascular surgery
ave followed a similar approachwhen they realized thatmany
ctions adopted in day-to-day clinical practice are supported
y lower-quality evidence only and that expert opinion in
hese areas is needed. A review of all practice guidelines
ublished by the American College of Cardiology and the
merican Heart Association showed that only 11% of their
ecommendations are classified as level A evidence and con-
luded that recommendations issued in the current American
ollege of Cardiology/American Heart Association clinical
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Volume 53, Number 5 Murad et al 1377practice guidelines are developed largely from lower levels of
evidence or from expert opinion.10
The rationale for providing such statements that de-
scribe “best practice” suggestions is that a consensus state-
ment made by experts in the field who conducted an
exhaustive literature search (1) will likely be appreciated by
busy practicing surgeons and (2) may plausibly be more
valid for patient care than a judgment call made at the point
of care without this background of expertise and evidence
appraisal. Nevertheless, the SVS emphasized that such
statements should be labeled clearly as consensus state-
ments and the resulting recommendations should have a
weaker or conditional nature. Practicing surgeons can de-
viate from these recommendations when a patient’s context
and clinical presentation differ from the average patient, for
whom guidelines are typically developed. These areas are
also highlighted as gaps in the literature and target for
future research. TheGrading of Recommendations, Assess-
ment, Development, and Evaluation (GRADE) system,
described thereafter, provides the appropriate framework
for developing and presenting such recommendations.
TheGRADE system. In generating practice guidelines,
the SVS has joined more than 40 other organizations11 and
adopted the GRADE system. GRADE is a state-of-the-art
system for separately judging and reporting the quality of
supporting evidence and the strength of clinical recommen-
dations. It also allows the incorporation of patients’ values
and preferences in the recommendations. These features
make the GRADE system helpful to users and provides the
clarity sought by the SVS.12 The methodology of guideline
development and the details of the GRADE system have
been introduced to the vascular surgery community in a
publication8 that accompanied the practice guidelines of
the management of vascular access. The steps undertaken
following this framework are described briefly.
Evaluating the quality of evidence. The first step in
applying the GRADE framework is evaluation of the qual-
ity of the evidence (ie, the degree of confidence in the
estimates of treatment effects). The quality, or confidence,
can be lowered because of (1) methodological limitations
of the included studies (eg, studies with large proportion of
patients lost to follow-up, lack of blinding in a randomized
trial, the presence of various biases, etc.), (2) inconsistency
across studies (ie, studies showing different treatment effect
of the same intervention), (3) indirectness (ie, the extent to
which the evidence applies to the specific clinical question
in terms of patients, interventions, and outcomes. For
example, applying the results of studies of younger patients
to an older patient), (4) imprecision (wide confidence
intervals that include both benefit and harm, typically due
to a small number of events), and (5) publication bias (ie,
studies showing null results are not published, or published
in lower-impact journals after a long period of time) (Table
I). Conversely, quality of evidence can increase when treat-
ment effect is large, a dose–response relationship is evident,
or residual (unadjusted) confounding is thought to
strengthen the association. Usually, the quality of evidence
is rated as high, moderate, low, and very low. In recent suidelines, the SVS decided to merge the two lower tiers of
he quality of evidence (low and very low) into one category—a
ecision made by other guideline developers, such as the
merican College of Chest Physicians.13 The strength of
linical evidence (Table II) is graded from A (high quality)
hrough C (low and very low quality). Although this deci-
ion streamlines guideline reports, it also indicates that
vidence that would have been considered at either high
isk of bias or very high risk of bias are now graded together
nd should be interpreted as being at very high risk of bias
nd as having the lowest confidence in the estimates of
ffect. This adaptation to make the recommendations more
ser-friendly for practicing physicians highlights the flexi-
ility of the GRADE framework.However, its implications,
s well as whether this modification achieves its goal, con-
inues to be uncertain.
Strength of recommendation. The strength of recom-
endation is categorized as grade 1, or strong, and grade 2,
r weak. It is determined by the following factors: the
uality of evidence, the balance between desirable effects
nd undesirable ones, the values and preferences, and the
esources and costs. Strength of recommendation has im-
ortant implications for the clinician. In grade 1 recom-
endations, the benefits of an intervention clearly out-
eigh its risk and burdens. All well-informed patients
ould choose such a treatment, and the physician, often
ithout a detailed knowledge of the underlying data, can
able I. Factors affecting evidence quality
actors lowering the quality of
andomized trials
Factors increasing the
quality of observational
studies
oor study methods and execution
(eg, blinding, concealed
allocation, follow-up)
Large magnitude of effect
nconsistency across trials All potential confounders
would strengthen the
association
ndirect evidence (eg, use of
surrogate outcomes, lack of
direct comparisons between
treatments)
Dose–response
relationship
mprecise or sparse results
eporting and publication biases
able II. Ratings the quality of evidence
uality of
vidence Rating Description
igh A Further research unlikely to change
confidence in estimate of effect
oderate B Further research likely to impact
confidence in estimate of effect
and may change estimate
ow C Further research very likely to impact
confidence in estimate of effect
and likely to change estimateecurely recommend it. Grade 2 recommendations are
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May 20111378 Murad et alweaker and reflect therapies where benefits and risks are
uncertain or more closely balanced. For such interventions,
the physician must be familiar with the evidence underlying
the recommendation, and the patient may choose different
options on the basis of their underlying values.
Outcomes chosen for decision making. Under the
GRADE framework, patient-important outcomes are cho-
sen for decision making; these outcomes affect the way the
patient feels, functions, or survives.14 For example, the
carotid guidelines committee considered death, stroke, and
myocardial infarction as the only outcomes driving their
recommendations for carotid revascularization. By com-
parison, the venous guidelines committee found that most
available evidence reported treatment effects on surrogate
outcomes, such as vein patency and valve competency. The
committee had to consider the evidence to be indirect (ie,
not directly pertinent to what guideline developers and
users need to know) and of lower quality, which affected
the strength of their recommendations.
Voting. Committees use consensus building and vot-
ing procedures to reach their final decisions on recommen-
dations. Each committee member votes on the final recom-
mendations using an ordinal scale with five possible
answers: a strong or weak recommendation for an interven-
tion, a strong or weak recommendation against an inter-
vention, or no opinion. The committee chair compiles and
reports the results to the committee for review. A recom-
mendation would be rated as weak if a consensus on the
direction (for vs against) is reached but a consensus on the
strength (weak vs strong) is not. Discrepant views can be
presented in the published version of the guidelines to
highlight the quality of the supporting evidence and to
provide implications for future research.
Peer review. The Document Oversight Committee of
the SVS conducts peer reviews of the guidelines docu-
ments. This committee consists of a panel of eight experts
not involved in any of the aforementioned steps. Commit-
tee members who participated in writing the guidelines
manuscript are excused from the review process.
Conflict of interest. Committee members are re-
quired to provide a detailed, explicit description of their
financial and intellectual conflicts of interest, consistent
with the policies of the Journal of Vascular Surgery. Addi-
tional measures used to manage conflicts of interest include
the multidisciplinary structure of guideline committees and
the involvement of a methodology group in the evidence
synthesis and guidelines integration.
PUBLISHED SVS GUIDELINES USING THE
GRADE SYSTEM
Guidelines developed from 2007 to 2010 included a
total of 74 recommendations for the management of ca-
rotid artery disease, vascular access for hemodialysis, endo-
vascular repair of aortic disease, thrombus removal for deep
venous thrombosis, and varicose veins. The quality of the
evidence was rated high (A) in only nine (12%) and was
mostly low to very low. In other words, the guideline
developers had extremely low confidence in the correctness of the estimates provided by the best evidence available.
he strength of the recommendations was level 1 (strong
ecommendation) in 48 (65%) of the recommendations
nd level 2 (weak recommendation) in 26 (35%). Some of
he stronger recommendations, in which the guideline
evelopers were more confident that patients receiving care
ligned with the recommendations would derive more
ood than harm, were based on lower-quality evidence.
his situation, which should not happen often, suggests
hat guideline developers made value judgments that super-
eded the research evidence.
An example of a strong recommendation associated with
ow-quality evidence is the one against carotid artery stenting
n asymptomatic patients with carotid stenosis.5 Although
etter data are available now,15 at the time the guidelines were
eveloped, no trials compared stenting with medical manage-
ent and the data comparing stenting to endarterectomy
ere sparse and imprecise. In developing this recommenda-
ion, the guideline developers put a relatively high value on the
voidance of potential downsides in the clinical context of an
nvasive procedure for a low-risk patient who has an unclear
isk-to-benefit ratio. Thus, despite low-quality evidence, the
ommittee issued a strong recommendation.
UTURE OUTLOOK
Despite the gradual improvement in the quality of
linical practice guidelines over time, many scholars have
uggested reform and further enhancements. Their propos-
ls have included the following areas: defined prerequisites
or membership in guideline groups, a change in guidelines
eadership from one edition to the next, inclusion of an
xpiration date after which a recommendation needs to be
evised, better representation of alternative interpretations
nd viewpoints, independent scientific review of guidelines,
nd a rigorous process for management of conflicts of
nterest.16 Although many of these suggestions are empiric
nd not necessarily validated, the GRADE framework, the
VS procedures, and the processes of guideline develop-
ent described thus far are consistent with state-of-the-art
ethods and follow rigorous methodologic approaches.
et, important challenges are unresolved. We describe four
otential areas in need of improvement.
atients’ values and preferences
The fact that the field of vascular surgery is facing evidence
t very high risk of bias that results in weaker inferences
ighlights the need for improved understanding of patients’
alues andpreferences.The current SVSguideline committees
re making assumptions about these values that they explicitly
escribe to demonstrate how these assumptions impact the
trength and direction of their recommendations. For exam-
le, committees assumed that patients seeking treatment for
aricose veins will opt for less invasive procedures and that
atients undergoing treatment of carotid artery disease will
alue avoiding a disabling stroke more than avoiding myocar-
ial infarction or even death.5 Although these assumptions
ay seem intuitive at face value, they likely differ across a range
f informed patients.
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Volume 53, Number 5 Murad et al 1379Guideline committeeswould be better informedwith better
research in this area, which is in its infancy. For example, survey-
ing a random sample of patients or conducting focus group
discussionsmay identify thedistributionof these values in a given
population and lead to the formulation of better recommenda-
tions—ones that better reflect the distribution of patients’ values
and preferences. Different perspectives need to be considered
when these values are elicited: those of patients at risk, patients
who had the outcomes at hand, and the general population that
pays taxes and insurance premiums to provide services to those
whohave theoutcomes.This issue is paramount, considering the
high proportion of grade 2 recommendations seen in the field of
vascular surgery.
Implementation tools
Most guidelines published in the literature across dif-
ferent disciplines fail to offer guidelines users the tools and
approaches needed to facilitate implementation and inte-
gration of the recommendations in their current practice.
These tools may include decision aids, innovative quality
improvement processes, and platforms for performance
feedback and audit. More specific to vascular surgery and
since many current recommendations are grade 2 (ie,
weaker recommendations that by definition apply to some
but not all patients), decision aids are clearly needed. Such
aids offer evidence-based information about the advantages
and disadvantages of the available options in order to
engage patients in the decision-making process, which in
turn increases the likelihood that the selected treatment will
better match patient values, preferences, and context.17,18
The quality of evidence
Many guidelines are necessarily based on low- or very-
low-quality evidence, a fact that must be recognized. Not
only is evidence from randomized and rigorously con-
ducted observational studies usually lacking, the existing
evidence in vascular surgery is often compromised by the
lack of comparison groups and the frequent use of surro-
gate outcomes, such as graft migration rates, graft patency
or target lesion revascularization, percentage thrombolysis,
and vein closure rates. Although such outcomes may be
appropriate in establishing the feasibility of new technol-
ogy, they should not drive utilization or determine the
standard of care. The vascular community must be wary of
such outcomes and, although often more costly, demand
the availability of patient-important outcomes before a
routine adoption of new technology.
Unfortunately, randomized trials in surgery can be
challenging to conduct for various reasons. This situation
has led to the current status of much of the surgical litera-
ture, in which only weak inferences and uncertainty can be
provided. Efforts to organize new prospective randomized
trials to provide higher-quality evidence of the effectiveness
of vascular and endovascular procedures should be encour-
aged. Yet, other potential solutions include the following.
(1) Conduct expertise-based trials. Instead of randomly
assigning patients to procedure A or B, randomly as- tsign patients to surgeon A who specializes in a partic-
ular procedure or to surgeon B who specializes in
another procedure. Hence, each surgeon performs the
procedure he or she is most capable of doing.
2) Use alternative randomization methods such as cluster
randomization (ie, the surgical centers, instead of pa-
tients, are randomized), using randomization ratios
other than 1:1 (ie, to allocate more patients to the
intervention arm), and outcome-adaptive randomiza-
tion methods (changing the allocation ratio according
to how patients are doing in a particular arm).
3) Conduct collaborative, multicenter randomized trials,
which are most relevant in the case of less common
diseases, such as aortic transection, to increase the
power and precision of studies and to lessen the possi-
bility of imbalances in prognosis at baseline, a key
limitation of small trials with few outcomes.
f randomization is not feasible, the design of observational
tudies can be improved. The creation of prospective disease
egistries is one possible improvement. In such registries, data
f consecutive patients are collected in the least biased way
eg, not voluntarily or selectively entered, with outcomes
djudicated properly and possibly by reviewers to whom the
tudy is blinded or have no perceived conflicts of interest).
ome statistical techniques such as propensity score matching
ay help in balancing the prognosis of study groups. How-
ver, these registries remain susceptible to the fundamental
ias of treatment allocation by choice rather than by chance, a
rocess of selection to treatment that may be associated with
utcomes, or the so-called selection bias. Although insuffi-
ient to overcome selection bias, analyses of these registries
an be stratified or adjusted according to a priori identified
rognostic variables and clinically relevant subgroups. Such
nalyses may offer new hypotheses about which patients ben-
fit differentially from a particular treatment.
Finally, as a caveat to the low- or very-low-quality
vidence underlying most guidelines, it must be appreci-
ted that these guidelines are subject to modification as
etter-quality evidence becomes available. For example,
ince the publication of guidelines on the management of
arotid artery disease and endovascular aneurysm repair,
ew evidence from randomized trials has become avail-
ble.15,19 The Appraisal of Guidelines, Research, and Eval-
ation instrument, used to appraise the quality of guide-
ines, considers a defined plan for guidelines renewal to be
characteristic of good-quality guidelines.20 The SVS plans
o periodically monitor the literature for new evidence and
pdate the guidelines, starting with the first publication
hat addresses the management of carotid disease.5
ost and resources
Incorporating cost considerations in decision making is
atural and intuitive and is a quality measure of good
uidelines.20 However, significant challenges have made
he incorporation of cost in guidelines uncommon. Health
are costs differ widely among jurisdictions and payer sys-
ems, change over time, depend on the philosophic per-
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political, are sensitive to issues that relate to the conflict of
interest of a guideline panel, and are associated with varying
attitudes and ethical concerns among physicians and pa-
tients. Thus, the GRADE approach has been to advocate
for a wider societal perspective on cost and to use the
concept of resource utilization instead of cost.21
Yet, the evidence supporting cost and resource alloca-
tion is quite weak for use in guideline formulation. Formal
economic modeling often is unavailable to support all
recommendations, and the process requires experienced
judgment and expertise in economic evaluation—both of
which rarely form part of guideline panels. The SVS has an
ongoing endeavor to systematically appraise the existing
economic models in the area of lower extremity revascular-
ization, comparing open bypass to endovascular interven-
tions, which may lead to development of a more compre-
hensive economic analysis model.
CONCLUSIONS
Despite the challenges and inconsistent availability of
high-quality evidence, the SVS maintains its effort to summa-
rize, synthesize, and present all the available evidence, along
with clear clinical practice recommendations, to help surgeons
and their patients in decision making. Although the SVS uses
state-of-the-art approaches, such as GRADE,12 innovations
are needed to improve the quality of evidence in the field and
to improve the clarity and usefulness of these guidelines,
which will lead to increased confidence in the advice vascular
surgeons provide to their patients. Given the limited quality of
the evidence, the issues with generalizability, and the impor-
tance of patient values, practice guidelines should not be
regarded as definitive or prescriptive.22 Consistent with the
tenets of evidence-based medicine, they should be used to
inform clinical decision making in the context of the physi-
cian’s clinical expertise and the patient’s underlying values and
preferences.
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